Daxor Corporation announced FDA 510(k) clearance (K251087) for its patent-pending next-generation rapid, compact, hand-held, lab-based Blood Volume Analyzer (BVA). The device quantifies a patient's blood volume against patient-specific norms, enabling precise fluid management across clinical conditions affecting millions of patients annually.
"For decades, clinicians without access to BVA have been forced to estimate a patient's blood volume status using indirect, often invasive, or imprecise methods," said Michael Feldschuh, Daxor's President and CEO. "This critical knowledge gap has impacted treatment decisions across numerous medical specialties. Daxor's next generation BVA device changes the game by delivering even faster, precise blood volume data anywhere there is access to a laboratory—from the hospital to the outpatient clinic."
Addressing a Multi-Billion Dollar Healthcare Crisis
Volume derangement represents a silent crisis driving a multi-billion annual healthcare burden. Conditions requiring accurate fluid management include heart failure (over seven million patients and one million hospitalizations annually), critical care and sepsis (7.4 million admissions), dialysis, surgical blood loss, traumatic injury, and syncope.
"Our diagnostic innovation is a game-changer for fluid management," said John L. Jefferies, MD, MPH, MBA, Daxor's Chief Medical Officer. "By using the gold standard indicator tracer dilution technique, we can overcome the inaccuracies of traditional clinical assessments, especially in patients with multiple and complex conditions. BVA provides precise, objective data, empowering value-based care through better outcomes and fewer hospitalizations."
Clinical Evidence Demonstrates Significant Mortality Reduction
Peer-reviewed studies show blood volume analysis guided care reduced heart failure one-year mortality by 86% (p<0.001). The technology also demonstrated shorter hospital stays, 56% fewer readmissions, and significantly lower healthcare costs. Data from a randomized control trial in the ICU showed significant benefit with BVA-guided care, lowering mortality by 66% in a cohort of predominantly septic/ARDS patients (p<0.03).
Enhanced Efficiency and Broader Clinical Application
Building upon the success of its predecessor, the Daxor BVA-100™, this next-generation analyzer redefines efficiency, enabling far broader use in clinical settings where resources are limited. The device offers three times faster results delivery, weighs just 7 pounds for easy transport between laboratory settings, and maintains laboratory-grade diagnostic precision.
The newly FDA-cleared system enables physicians in cardiology, nephrology, critical care, hematology, emergency medicine, and primary care to tailor treatment with confidence. By accurately measuring volume status, clinicians can avoid risks of hypovolemia—including tissue hypoperfusion, acute kidney injury, hypotension, syncope, and organ damage—as well as hypervolemia, which can lead to heart failure decompensation, accelerated disease progression, and further organ damage.
Research Foundation and Market Position
Research from leading institutions including Duke University Medical Center, the Cleveland Clinic, the Mayo Clinic, and the U.S. Department of Veterans Affairs has proven the utility of BVA-guided care. This approach has been shown to reduce mortality, readmissions, and hospital length of stay. With over 75,000 tests shipped and more than 50 years of groundbreaking research, Daxor continues to redefine precision diagnostics.
The new system was developed under contract with the U.S. Department of Defense, specifically the U.S. Army and the Defense Health Agency, positioning Daxor as the global leader in blood volume measurement technology.
